Neonc Technologies (NASDAQ:NTHI) CEO Purchases $115,500.00 in Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour acquired 35,000 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were acquired at an average price of $3.30 per share, for a total transaction of $115,500.00. Following the completion of the acquisition, the chief executive officer directly owned 3,183,000 shares in the company, valued at $10,503,900. The trade was a 1.11% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Neonc Technologies Trading Up 14.0%

Neonc Technologies stock opened at $3.41 on Friday. The stock has a 50 day moving average of $3.98 and a 200-day moving average of $5.18. Neonc Technologies Holdings, Inc. has a 52 week low of $2.95 and a 52 week high of $12.99.

Neonc Technologies (NASDAQ:NTHI) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Hedge Funds Weigh In On Neonc Technologies

A number of hedge funds have recently added to or reduced their stakes in NTHI. Bank of America Corp DE bought a new stake in Neonc Technologies during the second quarter valued at $1,017,000. BlackRock Inc. bought a new position in shares of Neonc Technologies in the 2nd quarter worth about $815,000. Global Retirement Partners LLC acquired a new position in shares of Neonc Technologies in the 2nd quarter valued at about $126,000. Finally, Westmount Partners LLC boosted its holdings in shares of Neonc Technologies by 355.2% in the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock valued at $893,000 after buying an additional 153,858 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on NTHI. BTIG Research reaffirmed a “buy” rating and set a $15.00 price target on shares of Neonc Technologies in a research report on Tuesday, September 8th. Wall Street Zen lowered Neonc Technologies from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings cut Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $16.00.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.